- Home
- FLR vs BLCO Comparison
FLR vs BLCO Comparison
Compare FLR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLR
- BLCO
- Stock Information
- Founded
- FLR 1912
- BLCO 1853
- Country
- FLR United States
- BLCO Canada
- Employees
- FLR N/A
- BLCO N/A
- Industry
- FLR Military/Government/Technical
- BLCO Ophthalmic Goods
- Sector
- FLR Industrials
- BLCO Health Care
- Exchange
- FLR Nasdaq
- BLCO Nasdaq
- Market Cap
- FLR 6.4B
- BLCO 5.6B
- IPO Year
- FLR N/A
- BLCO 2022
- Fundamental
- Price
- FLR $37.20
- BLCO $14.35
- Analyst Decision
- FLR Strong Buy
- BLCO Hold
- Analyst Count
- FLR 7
- BLCO 11
- Target Price
- FLR $54.71
- BLCO $19.10
- AVG Volume (30 Days)
- FLR 2.7M
- BLCO 678.8K
- Earning Date
- FLR 05-02-2025
- BLCO 04-30-2025
- Dividend Yield
- FLR N/A
- BLCO N/A
- EPS Growth
- FLR 2177.78
- BLCO N/A
- EPS
- FLR 12.30
- BLCO N/A
- Revenue
- FLR $16,315,000,000.00
- BLCO $4,791,000,000.00
- Revenue This Year
- FLR $13.71
- BLCO $6.53
- Revenue Next Year
- FLR $5.77
- BLCO $5.64
- P/E Ratio
- FLR $3.02
- BLCO N/A
- Revenue Growth
- FLR 5.43
- BLCO 15.56
- 52 Week Low
- FLR $34.01
- BLCO $13.16
- 52 Week High
- FLR $60.10
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- FLR 45.41
- BLCO 34.92
- Support Level
- FLR $34.69
- BLCO $13.88
- Resistance Level
- FLR $39.14
- BLCO $14.70
- Average True Range (ATR)
- FLR 1.15
- BLCO 0.47
- MACD
- FLR 0.28
- BLCO -0.11
- Stochastic Oscillator
- FLR 56.40
- BLCO 21.36
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. The firm serves a wide range of end markets including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.